Tjønnfjord GE - Search Results

1

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.

Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA; RITP study group. Ghanima W, et al. Among authors: tjonnfjord ge. Lancet. 2015 Apr 25;385(9978):1653-61. doi: 10.1016/S0140-6736(14)61495-1. Epub 2015 Feb 5. Lancet. 2015. PMID: 25662413 Clinical Trial.

2

[Immune thrombocytopenia--pathophysiology and treatment].

Ghanima W, Holme PA, Tjønnfjord GE. Ghanima W, et al. Among authors: tjonnfjord ge. Tidsskr Nor Laegeforen. 2010 Nov 4;130(21):2120-3. doi: 10.4045/tidsskr.09.1119. Tidsskr Nor Laegeforen. 2010. PMID: 21052113 Free article. Review. Norwegian.

3

Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries.

Holme PA, Tjønnfjord GE. Holme PA, et al. Among authors: tjonnfjord ge. Haemophilia. 2019 Jan;25(1):54-59. doi: 10.1111/hae.13625. Epub 2018 Nov 5. Haemophilia. 2019. PMID: 30394617

4

Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.

Ghanima W, Kahrs J, Dahl TG 3rd, Tjonnfjord GE. Ghanima W, et al. Among authors: tjonnfjord ge. Eur J Haematol. 2004 Jun;72(6):441-3. doi: 10.1111/j.1600-0609.2004.00257.x. Eur J Haematol. 2004. PMID: 15128424

5

Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency.

Tran HT, Tjønnfjord GE, Holme PA. Tran HT, et al. Among authors: tjonnfjord ge. Haemophilia. 2014 Jan;20(1):141-6. doi: 10.1111/hae.12256. Epub 2013 Aug 28. Haemophilia. 2014. PMID: 23992369

6

Haemophilic arthropathy: long-term outcomes in 107 primary total knee arthroplasties.

Westberg M, Paus AC, Holme PA, Tjønnfjord GE. Westberg M, et al. Among authors: tjonnfjord ge. Knee. 2014 Jan;21(1):147-50. doi: 10.1016/j.knee.2013.09.010. Epub 2013 Oct 7. Knee. 2014. PMID: 24156923

7

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE. Berentsen S, et al. Among authors: tjonnfjord ge. Blood. 2004 Apr 15;103(8):2925-8. doi: 10.1182/blood-2003-10-3597. Epub 2003 Dec 30. Blood. 2004. PMID: 15070665 Free article. Clinical Trial.

8

Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.

Tjønnfjord GE, Holme PA. Tjønnfjord GE, et al. Vasc Health Risk Manag. 2007;3(4):527-31. Vasc Health Risk Manag. 2007. PMID: 17969383 Free PMC article. Review.

9

Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.

Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE. Holme PA, et al. Among authors: tjonnfjord ge. Haemophilia. 2009 May;15(3):727-32. doi: 10.1111/j.1365-2516.2009.02017.x. Haemophilia. 2009. PMID: 19320748

10

[Hairy cell leukemia treated with cladribine].

Ghanima W, Heldal D, Tjønnfjord GE. Ghanima W, et al. Among authors: tjonnfjord ge. Tidsskr Nor Laegeforen. 2002 Apr 30;122(11):1094-7. Tidsskr Nor Laegeforen. 2002. PMID: 12043051 Free article. Norwegian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

231 results

Search Page